Loading clinical trials...

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib | Clinical Trials | Clareo Health

TERMINATEDPHASE1

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

Phase 1/2 Study Epigenetic Modification of BRAF-mutated Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

NCT01876641•Mohammed M Milhem

View on ClinicalTrials.gov

Summary

The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.

Detailed Description

The primary objective of the Phase I portion of this study is to evaluate the safety and tolerability of the proposed schedule of decitabine and Vemurafenib plus Cobimetinib in the treatment of metastatic melanoma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female \>/= 18 years old ECOG Performance Status of \</= 2
•Meet the following lab criteria:
•Hematology Neutrophil count \>1500/mm3 Platelet count \>100,000/mm3 Hemoglobin \>/= 9 g/dL Biochemistry AST/ALT \</= 2.5 x upper limit of normal (ULN) or \</= 5.0 x ULN if the transaminase elevation is due to disease involvement Serum bilirubin \</= 1.5 x ULN Serum creatinine \</=1.5 x ULN or estimated creatinine clearance \>/= 50 ml/min by Cockcroft-Gault equation Total serum calcium (corrected for serum albumin) \>/= 8.5 mg/dL or ionized calcium \>/= 3.8 mg/dL Serum potassium \>/= LLN Serum sodium \>/= LLN Serum albumin \>/= 3g/dl Baseline MUGA or ECHO must demonstrate LVEF \>/= the lower limit of the institutional normal.
•TSH and free T4 within normal limits, may be on thyroid hormone replacement Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first dose of study drug. Willing to use 2 methods of contraception, one being a barrier method during the study and for 3 months after last study drug dose.
•Any patient with metastatic melanoma (any site) whose tumor is V600EBRAF positive, regardless of prior treatment.
•Prior treatment with Vemurafenib will be allowed Must not have taken a hypomethylating agent. Must have had disease progression on or following most recent treatment regimen or on presentation for the first time with metastatic disease.
•Patients with CNS disease are eligible for treatment only after their CNS disease has been directly addressed with radiation therapy.

Exclusion Criteria

•Prior Decitabine for the treatment of cancer
•Impaired cardiac function including any one of the following:
•Screening ECG with a QTc \> 460 msec confirmed by central lab prior to enrollment; congenital long QT syndrome; History of sustained ventricular tachycardia; History of ventricular fibrillation/torsades de pointes; Bradycardia defined as heart rate (hr) \< 50 beats per minute; Patients with a pacemaker and hr \>/= 50 beats per minute are eligible; Patients with a myocardial infarction or unstable angina within 6 mos of study entry; CHF (NYHA class III or IV); Right bundle branch block and left anterior hemiblock; Uncontrolled hypertension Concomitant use of drugs with a risk of causing torsades de pointes Concomitant use of CYP3A4, CYP1A2, or CYP2D6 substrates Unresolved diarrhea \> CTCAE grade 1 Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Vemurafenib Other concurrent severe or uncontrolled medical conditions Patients who have received prior therapies will be allowed to enroll after a wash-out period: Chemotherapy - 3 week (wk) wash-out; Oral agents - 2 wk wash-out (Except Vemurafenib, no wash-out period); Investigational agents - 3 wk wash-out; Immunotherapy - 4 wk wash-out; Palliative radiation therapy to bone/brain - 2 wk wash-out; Major radiation or surgical procedure - 3 wk wash-out Concomitant use of any anti-cancer or radiation therapy. No measurable disease Pregnant, breast-feeding women or WOCBP not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment. One method of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or have not been naturally postmenopausal for at least 12 consecutive months (who has had menses any time in the preceding 12 consecutive months).
•Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment. One of these methods must be a condom History of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin Known positivity for HIV or hepatitis C Any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent

Locations (1)

University of Iowa Hospitals & Clinics

Iowa City, Iowa, United States

Key Dates

Start Date

October 1, 2013

Primary Completion Date

June 1, 2018

Completion Date

September 1, 2018

Last Updated

September 19, 2018

Enrollment

ACTUAL participants

Conditions

Metastatic MelanomaMelanomaBRAF-mutated Metastatic MelanomaV600EBRAF-mutated Metastatic Melanoma

Interventions

Vemurafenib + Cobimetinib, Decitabine

DRUG

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma